Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elusys Therapeutics

This article was originally published in Start Up

Executive Summary

The core technology on which EluSys Therapeutics is based is a bispecific antibody technology with broad potential to bind to and clear toxins, auto-antibodies, and pathogens. That technology, called the HP System, is based on the mechanism of immune adherence. In response to a foreign substance (an antigen) entering the bloodstream, the immune system produces antibodies that bind the antigen, forming an immune complex, which in turn activates the complement system. A complement protein attaches to the immune complex and binds to the CR1 receptor of the complement system, which is found on all red blood cells (RBCs). The bound immune complex is then transported to the liver, where it is stripped off the RBC and destroyed by macrophages. Taylor's invention uses a heteropolymer-an antibody specific for both the CR1 receptor and the target antigen-to clear the target antigen without having to activate the complement system, which improves the efficiency of the clearance process.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC090175

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel